
CStone Pharmaceuticals expands sugemalimab reach to Oceania
CStone Pharmaceuticals has signed an exclusive agreement with Arrotex Pharmaceuticals to commercialize the anti-PD-L1 antibody sugemalimab in Australia and New Zealand. The partnership grants Arrotex rights to distribute the drug across several oncology indications, pending regulatory approval from the Therapeutic Goods Administration.
























